Olmetec (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmetec, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adults with essential hypertension, either as monotherapy or in combination with other antihypertensive agents.

GNH USA supplies Olmetec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. GNH USA’s global network ensures timely delivery, temperature‑controlled logistics where required, and compliance with local regulatory requirements.

Olmesartan medoxomil (Olmetec) is an Angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Hypertension with type 2 diabetes: assists in achieving blood pressure goals while supporting renal protection. - Hypertension in chronic kidney disease: provides effective blood pressure control in patients with renal impairment.

Olmesartan medoxomil may be associated with several adverse reactions, ranging from mild to serious. Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose or watery stools. - Cough: dry throat irritation. - Nausea: feeling of queasiness or urge to vomit. - Back pain: mild discomfort in the lumbar region. - Peripheral edema: swelling of the lower extremities. Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Hyperkalemia: elevated blood potassium levels. - Acute renal failure: sudden decline in kidney function. - Hepatic injury: signs of liver dysfunction. - Severe hypotension: markedly low blood pressure. - Myocardial infarction: rare occurrence of heart attack. - Renal artery stenosis: worsening kidney function in patients with pre‑existing narrowing.

When prescribing Olmesartan medoxomil, clinicians should observe several precautionary measures to ensure safe use. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium measurement: monitor for hyperkalemia, especially with concomitant potassium‑sparing agents. - Pregnancy avoidance: discontinue in women who are pregnant or planning pregnancy. - Elderly dosing: start with lower dose and titrate cautiously in older patients. - Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Aliskiren (in diabetes): combined use may increase risk of renal impairment, hyperkalemia, and hypotension. - Dual ARB/ACE inhibitor therapy: additive blood pressure lowering may cause severe hypotension and kidney injury. - Potassium‑sparing diuretics: risk of dangerous hyperkalemia. - NSAIDs: may reduce antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity. Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect. - Cyclosporine: can raise olmesartan plasma concentrations. - Rifampin: may decrease olmesartan effectiveness. - Beta‑blockers: additive blood pressure reduction, monitor for bradycardia. - Antidiabetic agents: monitor glucose control as blood pressure changes may affect glycemic levels.